Form 4: Twist Bioscience Director Keith Crandell Reports Acquisition of Shares

Director Keith Crandell reports acquisition of Twist Bioscience shares through an equity award and discloses beneficial ownership.

Summary

• Keith Crandell, a director of Twist Bioscience Corp, filed a Form 4 on February 7, 2025, reporting changes in beneficial ownership.
• On February 5, 2025, Crandell acquired 4,472 shares of common stock through an annual equity award.
• The shares were acquired at a price of $0.
• Following the transaction, Crandell directly owns 22,476 shares of common stock.
• Crandell also indirectly owns 76,047 shares through the Keith L. Crandell Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of share acquisition by a director, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The annual equity award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder confidence.

Key Dates